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Abstract
Background: The relationship of dietary fiber to overall health is of great importance, as beneficial
effects have been demonstrated with the use of fiber from diverse sources, some traditional, other
novel. PolyGlycopleX® (PGX®) is a unique proprietary product composed of three water-soluble
polysaccharides, that when processed using novel technology give rise to a final product – a soluble,
highly viscous functional fiber.
Methods: Because of its potential use in food and dietary supplements, a randomized, double-
blind, placebo controlled clinical study was conducted to evaluate the tolerance to PGX ingestion
for 21 days, to a maximum dose level of 10 g per day, in healthy male and female volunteers. The
main objective of the study was to evaluate the overall gastrointestinal (GI) tolerance, while
secondary objectives were to evaluate possible changes in hematological, biochemical, urinary and
fecal parameters.
Results: Results show that PGX is well tolerated as part of a regular diet with only mild to
moderate adverse effects, similar to those seen with a moderate intake of dietary fiber in general,
and fruits and vegetables. Because PGX is a highly viscous, functional fiber, it also demonstrates
several physiological responses including, but not limited to maintaining healthy total and LDL
cholesterol and uric acid levels.
Background
The Institute of Medicine (IOM) report [1] on dietary fiber
recognizes the importance of fiber to overall health and
acknowledges the diversity of edible, non-digestible car-
bohydrates in the human food supply, while allowing for
flexibility to incorporate new fiber sources developed in
the future. In 2002, the Food and Nutrition Board of the
Institute of Medicine published the report on fiber, intro-
ducing new definitions and classifications, and discerning
between fiber found naturally in plants (dietary fiber; e.g.,
cellulose, pectin, gums, hemicellulose, β-glucans, and
fiber contained in oat and wheat bran), and isolated or
synthetic fiber that may be used in dietary supplements or
added to foods (potential functional fiber for food labeling;
isolated (e.g., resistant starch, pectin, and gums), animal,
or commercially produced carbohydrates) [1]. The new
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IOM definition for total fiber is "the sum of dietary fiber
and functional fiber", attempting to encompass both the
physical characteristics and the physiological effects of
fiber in humans [1].
Dietary fibers display a wide range with regards to viscos-
ity. Certain dietary fibers including, but not limited to
pectins,  beta-glucans, psyllium, and gums have unique
physicochemical properties that allows them to form vis-
cous solutions or gels when mixed with liquids, the degree
of thickening being directly dependent on the chemical
composition [2,3].
Gums consist of a diverse group of polysaccharides. These
hydrophilic polymers have water binding properties and
are used in foodstuff to stabilize emulsions, prevent ice
recrystallization and impart organoleptic properties. Sev-
eral gums are approved by the Food and Drug Administra-
tion (FDA) for their technical functional effects as
stabilizers and thickeners (21 Code of Federal Regulations
(CFR) §170(o)(28)).
One physicochemical property of fiber, viscosity, has been
investigated and found to affect several possible physio-
logical responses [4,5]. In general, when fiber is mixed
with food and human digesta in the gut, a firm soluble
polysaccharide/food matrix is formed leading to delay of
gastric emptying. Fiber, and especially viscous fiber will
result in a sensation of fullness, and possible alterations in
blood glucose and cholesterol concentrations, and slower
transit time through the small intestine [4,5].
Dietary fibers have also been classified based on solubility
and fermentability. Soluble dietary fibers including beta-
glucans, mucilages (e.g., psyllium), pectins, some hemi-
celluloses and gums, are dispersible in water. Pectins, beta-
glucans, gums, inulin and oligofructose are dietary fibers
that are also readily fermented by bacteria in the colon
leading to the formation of short chain fatty acids (prima-
rily acetate, propionate, and butyrate) and gases (carbon
dioxide, methane, hydrogen) [1,6-8].
PolyGlycopleX (PGX) (PolyGlycopleX® and PGX® are reg-
istered trade marks) is a proprietary product manufac-
tured with the use of novel technology under good
manufacturing practices (GMP). The product is composed
of three highly-purified, water-soluble polysaccharides:
konjac powder, sodium alginate, and xanthan gum. The
three gums act synergistically to form strong bonds that
lead to a level of viscosity that is 3 to 5 times higher than
any known individual polysaccharide. The final product is
a soluble highly viscous functional fiber that can be used to
provide consumers with a supplementary source of fiber
in the diet. The present clinical study was designed to eval-
uate the tolerance to PGX ingestion for 21 days, to a max-
imum dose level of 10 g per day, in healthy male and
female volunteers.
In pre-clinical testing, PGX was administered in a 90-day
feeding study at dietary concentrations of 0, 12,500,
25,000 and 50,000 ppm to male and female Sprague
Dawley rats [9]. Results showed no toxicological effects
from the use of the test substance in any of the test groups,
indicating a no-observed-adverse-effect-level (NOAEL)
for PGX at the highest dose tested, corresponding to an
average daily intake of 3219 and 3799 mg/kg bw/day in
male and female rats, respectively [9].
Methods
Objectives
The main objective of the study was to evaluate the overall
gastrointestinal (GI) tolerance to the fiber, while second-
ary objectives were to evaluate GI symptoms and signs
(clinical examination) upon repeated consumption of
PGX by healthy men and women for 21 days, and assess
any effects on blood biochemical, hematological, urinary
and fecal analysis.
Subjects and methods
Study population
Eighty-eight volunteers were screened for the study. Fol-
lowing selection, 54 healthy subjects, 25 (46.3%) males
and 29 (53.7%) females, ranging in age from 18 to 55
(mean age 31.6 ± 10.5 years) entered the clinical trial. All
subjects were deemed healthy, based on physical exami-
nation (including heart rate, blood pressure, auscultation
of heart and lungs, and abdominal palpation and auscul-
tation), electrocardiogram (ECG) and laboratory tests that
were within normal limits. The height of the subjects
ranged from 155 cm to 191 cm (mean 170.9 ± 8.3 cm),
the weight ranged from 48.5 to 88.6 kg (mean 66.5 ± 8.6
kg), and the calculated body mass index (BMI) ranged
from 18.4 to 28.4 kg/m2 (mean 22.7 ± 2.2 kg/m2).
Subjects were randomly assigned to one of two groups:
study group (PGX) (14 males and 13 females), and con-
trol group (skim milk powder) (11 males and 16
females). All 54 subjects completed the clinical study.
Inclusion/Exclusion criteria
Included in the study were non-smoking (or smoking less
than five cigarettes per day), healthy (based on physical
examination, medical history, ECG and laboratory tests),
males and females, 18 to 55 years of age, with a BMI
between 18.5 and 29.9 kg/m2, and a stable weight for the
prior two months, agreeing to eat cereals and yogurt, 2
times per day as part of two out of three main meals, for 3
consecutive weeks.Nutrition Journal 2009, 8:9 http://www.nutritionj.com/content/8/1/9
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Exclusion criteria used for the study are found in Table 1.
Subjects were allowed to withdraw from the study at any
time and irrespective of reason, or because of a serious
adverse event.
Study design
The clinical trial was randomized, double-blind, placebo-
controlled, lasting three weeks, in addition to a two-week
enrollment period. The outpatient study was conducted at
a single research facility in accordance with the Declara-
tion of Helsinki (Edinburgh, 2000), and following Good
Clinical Practice Guidance (ICH E6), and local (French)
regulatory requirements. The protocol was approved prior
to study initiation by the French ethics committee
(Comité de Protection des Personnes (CPP) Sud-Est III)
and health authorities (DGS). There were no major proto-
col deviations identified during the study. Written
informed consent was obtained from all subjects prior to
study commencement.
Study products
The test product used in the study was PolyGlycopleX
(PGX) supplied by the sponsor (Inovobiologic; Calgary,
Alberta Canada). Two and a half grams of PGX were
ingested BID (L. bis in die, or twice a day) as part of two
main meals (breakfast and/or lunch, and/or dinner), for
the first seven days, followed by 5 g PGX BID for the last
14 days of the study. The control product selected for use
in the study, based on color and orosensory (texture sim-
ilarity) match to the test product was a skimmed milk
powder taken as 2.5 g BID for one week and then 5 g BID
for the remainder of the study. The composition of the
control product included 35.5% proteins, 51.7% carbohy-
drates, 0.80% lipids, 1.29% calcium, 0.11% magnesium
and 0.95% phosphorous.
Test and control products (2.5 g) were pre-mixed with 10
g breakfast cereals (Extra Pépites, Kellogg's®) (the amount
of fiber supplied by the cereal portion was 0.45 g) by
CRID Pharma, France. Each container was then packaged
with Le yogourt nature (plain) de Danone, a commer-
cially available yogurt (135 ml); the pre-mixed product
and yogurt were combined by each subject prior to inges-
tion. Test and control products were packaged individu-
ally for each subject, as ready-to-use portions, and were
supplied in strictly identical neutral packaging, making it
impossible for subjects and investigators to distinguish
one from the other, therefore ensuring the double blind-
ing for the study. The products were packaged and
released by CRID Pharma, France.
Selection of doses for the study
The tolerance of PGX was tested compared to the literature
values established for other similar carbohydrates (e.g.,
fiber). Therefore, it was decided to evaluate the tolerance
to ingestion of PGX for up to 10 g per day.
Study parameters
The parameters assessed during the clinical trial included
GI discomfort (intensity of abdominal pain and nausea,
flatulence, vomiting, intestinal rumbling, bloating and
pain, stool frequency and consistency), plasma chemistry,
hematology, urine, feces and plasma vitamin levels. The
biochemical parameters analyzed included glucose,
sodium, potassium, chloride, magnesium, calcium, zinc,
creatinine, urea, uric acid, total protein, albumin, total
bilirubin, alkaline phosphatase, aspartate transaminase
(AST; or aspartate aminotransferase), alanine transami-
nase (ALT; or alanine aminotrasferease), gamma-glutamyl
transpeptidase (GGTP; or gamma-glutamyl transferase
(GGT)), lactate dehydrogenase (LDH), creatinine phos-
phokinase (CPK), total cholesterol, high-density lipopro-
tein (HDL) cholesterol, low-density lipoprotein (LDL)
cholesterol, triglycerides, ferritin, and thyroid stimulating
hormone (TSH). Hematological testing included red
blood cells, hematocrit, hemoglobin, mean corpuscular
Table 1: Exclusion criteria
Abnormal physical examination
History of GI disease (i.e., gastric ulcers, irritable bowel disease, history of bowel obstruction and colon cancer)
History of abdominal surgery (exception: appendectomy)
Pregnant or beast feeding women
BMI > 30 kg/m2
Metabolic disorders (i.e., diabetes, and metabolic syndrome)
Using prescription medications, H2 blockers*, anti-acids, OTC**, dietary & herbal supplements
Involved in a weight loss program
Being treated for eating disorders
Having participated in another clinical trial in the previous month
Having received general anesthesia in the previous month
Refusing to consume the foods provided in the study
Known allergies to milk, nuts, wheat, soy, oat, and barely
Refusal to sign consent
*H2 blockers, also known as histamine-2 receptor antagonists, are drugs that prevent or block the production of gastric acid.
**OTC – over-the-counterNutrition Journal 2009, 8:9 http://www.nutritionj.com/content/8/1/9
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hemoglobin, mean corpuscular hemoglobin concentra-
tion, mean corpuscular volume, leucocytes, neutrophils,
eosinophils, basophils, lymphocytes, monocytes and
platelets. Urinalysis tested the pH, glucose, proteins,
blood, and ketones, while stool analysis tested the pH,
wet and dry matter, and short chain fatty acids (SCFA; I-
butyrate, N-butyrate and the ratio of butyrate/(acetate +
propionate). Plasma levels for vitamins A, B1, B6, B12, C,
1,25 OH vitamin D, E, and K were also tested during the
study.
Biochemical analyses were performed on the multi-para-
metric automated system Roche/HITACHI 912, Roche
Diagnostics, with a bi-directional connection. All param-
eters were analysed using commercially available kits. No
adaptation of the commercial methods was made. Meth-
ods of analysis are found in Appendix I [see additional file
1].
Visits
Physical examinations were performed on all subjects at
V0, V2 and V3 visits, and were all within normal limits.
Throughout the duration of the study, the clinical condi-
tion of each subject was assessed during four separate vis-
its: V0 (screening); V1 (baseline visit), V2 (following one
week of consumption of 5 g per day of the assigned prod-
uct), and V3 (following two weeks of consumption of 10
g per day of the assigned product).
Screening (V0) took place between Day -15 and Day -1, at
which time the informed consent was reviewed with each
volunteer and signed. Each subject underwent a physical
examination including recording of the height, weight,
heart rate, orthostatic blood pressure (5 minute supine
and 1 minute standing), auscultation of the heart and
lungs, and palpation and auscultation of the abdomen for
bowel sounds.
At baseline visit (V1; Day 0), subjects were randomized to
either test or control group, and underwent blood and
stool sampling. Volunteers received diaries and pre-pack-
aged products that included 2.5 g of the test or control
product to be consumed BID for 7 days.
At the visit following one week (V2; Day 8 ± 1) of con-
sumption of 5 g of the test or control product per day, the
subjects underwent evaluation of clinical tolerance fol-
lowing the use of 2.5 g test or control products BID, and
provided additional blood and stool samples. The sub-
jects turned in their diaries and empty product containers,
or unused product, and were provided with new diaries
and pre-packaged products for the remainder of the study.
They were instructed to consume 5 g of the test or control
product, BID for 14 days.
At the visit following two weeks (V3; Day 22 ± 2) of con-
sumption of 10 g of the test or control product per day, the
subjects underwent evaluation of clinical tolerance fol-
lowing the use of 5 g test or control products BID, and
provided additional blood and stool samples. The sub-
jects turned in their diaries and empty product containers,
or unused product.
Diet
Subjects were asked to abstain from consuming fiber-rich
foods, and to adhere to a low-fiber diet of approximately
10 g per day.
Evaluation of GI signs and symptoms
The main assessment criteria were conducted using self
evaluation of GI discomfort during the preceding week as
reported by the subject at each visit, while the secondary
criteria were performed using weekly mean evaluation of
daily values of intestinal symptoms, clinical evaluation by
the investigator, and laboratory analysis results (blood
chemistry and stool analysis). Subjects recorded the
intake of test and control product and the presence and
intensity of digestive symptoms in individual diaries,
which were handed in at subsequent visit. The recorded
parameters and their intensity were based on each sub-
jects' self evaluation of the stool frequency, stool consist-
ency, and GI discomfort (flatulence, borborygmus,
meteorism, abdominal pain, nausea, and vomiting). The
same parameters were also evaluated at the V2 and V3 vis-
its through the use of Visual Analog Scale (VAS is "a test-
ing technique for measuring subjective or behavioral
phenomena (as pain or dietary consumption) in which a
subject selects from a gradient of alternatives (as from "no
pain" to "worst imaginable pain" or from "every day" to
"never") arranged in linear fashion") [10]. The VAS scale
used in the study was from 0 (none) to 100 (very intense)
and was completed by each subject in the presence of the
investigator. Additionally, clinical examinations of indi-
vidual subjects were conducted at each visit by the inves-
tigator that included, but was not limited to palpation of
the abdomen for signs of discomfort or tenderness, and
auscultation of the abdomen for hypo- or hyperactive
bowel sounds.
Signs and symptoms were recorded through out the study
and their occurrences analyzed statistically. Signs  were
defined as any abnormality indicative of disease, discover-
able on examination of the patient; an objective symptom
of disease, in contrast to a symptom which is a subjective
sign of disease [11].
The frequency and intensity of signs and symptoms deter-
mined the threshold of GI tolerance.Nutrition Journal 2009, 8:9 http://www.nutritionj.com/content/8/1/9
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Compliance
Compliance with the instructions provided at commence-
ment of the study was assessed throughout the study. At
each visit, subjects were asked to turn in their diaries, and
at V2 and V3 each subject was required to bring back all
used packaging and unused product. The following for-
mula was used to determine compliance:
% compliance = number of products taken/theoretical
number of products to be taken × 100
Stool collection
Forty eight hours prior to each visit, subjects were asked to
collect one stool sample in designated containers. Stool
samples were dropped off by each subject at the study site
within twelve hours of collection, and were stored at 5 ±
3°C until analysis, which was conducted using standard
laboratory methods described in the protocol. The time
from collection of the stool samples to analysis was gen-
erally 24 hours and never exceeded 36 hours.
Concomitant treatments
No concomitant drug treatment was allowed during the
study. However, under special circumstances, and prop-
erly documented in the case report form (CRF) the occa-
sional use of paracetamol was allowed, as well as that of
prescription medication when approved by the investiga-
tor. Depending on the event and medication used, re-eval-
uation of the continued participation of the subject in the
study was assessed and shared immediately with the spon-
sor, especially in case of prolonged use of oral antibiotics.
Statistical analysis
The statistical analysis plan was written, validated and
included in the protocol, while the statistical analysis was
conducted at the conclusion of the clinical study. All indi-
vidual data for all the subjects in the study were presented
in data listings, sorted by group of product, subject, and
visit. Demographic and baseline characteristics data were
summarized by group of product and overall subjects.
Demographic characteristics (sex, age, weight, height, and
BMI), vital signs (blood pressure and heart rate), biology
(biochemistry, plasma vitamin levels, hematology, and
urinalysis), stool analysis, self evaluation parameters by
the subjects: stool frequency, stool consistency, GI dis-
comfort symptoms (flatulence, borborygmus, meteorism,
abdominal pain, nausea, and vomiting), and clinical eval-
uation of abdominal signs, were compared between test
and control groups using analysis of variance or Mann-
Whitney-Wilcoxon test for quantitative parameters, using
chi-2 test or Fisher's exact test for qualitative parameters.
In the case that normality of distribution of the main cri-
terion was not respected, the main criterion was com-
pared using Mann-Whitney-Wilcoxon test (with t
approximation) on value and change from baseline of
parameter at V3. Test and control products were com-
pared using ANOVA or Wilcoxon test, depending on the
normality of the distribution. The normality of distribu-
tion was tested by a Shapiro-Wilk's test.
Results
Fifty four healthy volunteers (25 males and 29 females),
ranging in age between 18 and 55 years, entered into and
completed a three-week study devoted to assessing the tol-
erance of PGX when ingested twice daily for three weeks
as part of a low-fiber diet to a maximum dose level of 10
g per day. The subjects' baseline clinical and biochemical
characteristics were not statistically different. Statistical
analysis of VAS based on the self evaluation of GI discom-
fort showed no differences between test and control
groups on the intensity of flatulence, intestinal rumbling,
bloating, nausea and vomiting at V2 and V3 (Wilcoxon
test; p = 0.3907 and p = 0.3722; p = 0.6360 and p =
0.8161; and p = 0.2402 and p = 0.1251; p = 0.8251 and p
= 0.7101; p = 0.8945 and p = 0.9169, respectively), or on
the intensity of abdominal pain at V2 and V3 (Wilcoxon
test; p = 0.2945 and p = 0.1923, respectively) during the
same visits.
Compliance with the instructions provided and intake of
the test and control products was assessed throughout the
study. The mean average compliance at V2 and V3 (%) for
the control group was 100% and for the test group was
99.6%.
The statistical analysis showed no differences between test
and control groups on averaged flatulence per day, or aver-
aged intensity of borborygmi and bloating per day, vomit-
ing, or number of stools at V2 week 1, or at V3 weeks 2 +
3, V3 week 2 or V3 week 3. There was no difference
between test and control group on averaged intensity of
abdominal pain per day at V2 week 1 or at V3 weeks 2 + 3,
V3 week 2; however, the averaged intensity of abdominal
pain per day was statistically significantly higher in the test
than control group in V3 week 3 (Wilcoxon test; p =
0.0160). The statistical analysis showed that the average
intensity of nausea per day was statistically higher in the
test than in the control group at V3 week 2 (Wilcoxon test;
p = 0.0055), but not at V2 week 1, V3 week 3 and V3
weeks 2 + 3.
At V2, the statistical analysis showed that the consistency
of stools was softer in the test than in the control group,
although not statistically different (Wilcoxon test; p =
0.0684). However, at V3, there was no difference in stool
consistency between the test and control groups (Wil-
coxon test; p = 0.3116). The statistical analysis showed no
difference between test and control groups on wet stool
weight at V2 or V3, or stool pH. However, at visit V2, theNutrition Journal 2009, 8:9 http://www.nutritionj.com/content/8/1/9
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percentage of dry matter was statistically higher in the con-
trol than in the test group (ANOVA; p = 0.0013).
Stool analysis for composition of total short chain fatty
acids (SCFA), I-butyrate, N-butyrate and ratio composi-
tion of butyrate/(acetate + propionate), showed no prod-
uct effect between test and control groups on total SCFA,
on each SCFA component, or on the ratio of butyrate/
(acetate + propionate), at baseline, V2, or V3 visits.
The statistical analysis showed no product effect between
test and control groups for each urinary (pH, glucose, pro-
teins, blood, and ketones), or hematological parameter
(red blood cells, hematocrit, hemoglobin, mean corpus-
cular hemoglobin, mean corpuscular hemoglobin con-
centration, mean corpuscular volume, leucocytes,
neutrophils, eosinophils, basophils, lymphocytes, mono-
cytes and platelets) evaluated at baseline, V2, or V3 (data
not shown).
The biochemical parameters evaluated at baseline, V2 and
V3 included glucose, sodium, potassium, chloride, mag-
nesium, calcium, zinc, creatinine, urea, uric acid, total
protein, albumin, total bilirubin, alkaline phosphatase,
aspartate transaminase (AST), alanine transaminase
(ALT),  gamma-glutamyl transpeptidase (GGTP), lactate
dehydrogenase (LDH), creatinine phosphokinase (CPK),
total cholesterol, high-density lipoprotein (HDL) choles-
terol, low-density lipoprotein (LDL) cholesterol, triglycer-
ides, ferritin, and thyroid stimulating hormone (TSH).
The statistical analysis showed no significant differences
between test and control groups for each biochemical
parameter evaluated at baseline, V2 or V3, except for total
cholesterol, LDL cholesterol, GGTP and uric acid.
The results for fasting total cholesterol (mmol/l), HDL
cholesterol (mmol/l), LDL cholesterol (mmol/l) and fast-
ing triglycerides at baseline, V2 and V3 are found in Table
2. The decrease in total cholesterol and LDL cholesterol
levels were statistically greater in the test than control
group, at visits V2 and V3. A decrease in GGTP and uric
acid levels were observed in test versus control groups at
V2 and V3, but statistically significant only at V2 (Wil-
coxon test; p = 0.0284, ANOVA; p = 0.0316, respectively).
At V3, uric acid levels in the PGX and control groups were
similar and both were approximately 9% lower than at
baseline (Table 3). The statistical analysis showed no sig-
nificant differences between test and control groups for
each plasma vitamin level (A, B1, B6, B12, E, and K) at base-
line, V2 or V3, except for vitamin D and C. At visit V2, vita-
min D increased level was statistically higher in the test
than in the control group (Wilcoxon test; p = 0.0159),
while at visit V3, vitamin C was significantly increased
over control (ANOVA; p = 0.0324) (Table 4).
Tolerance
During the study period, 8 of 27 (29.6%) subjects
reported the occurrence of eleven adverse events in the
control group and 9 of 27 (33.3%) subjects reported the
occurrence of ten emergent adverse events in the test
group. The adverse events were of mild to moderate inten-
sity, except one severe episode of headache, unrelated to
product intake. All the adverse events occurring during the
study were resolved before the end of the study and
required no additional follow up. Of the total number of
adverse events, 14 concerned GI signs and symptoms: five
occurred after intake of the control product and nine
occurred after intake of test product. The relationship to
study product was considered "unrelated" by the principal
investigator for nine adverse events: one episode each of
Table 2: Total, HDL and LDL cholesterol and triglyceride levels at baseline, V2 and V3 visits (N = 54)
Fasting total cholesterol 
(mmol/l)
HDL cholesterol (mmol/l) LDL cholesterol (mmol/l) Fasting triglycerides (mmol/l)
Control PGX Control PGX Control PGX Control PGX
N2 7 2 7 2 7 2 7 2 7 2 7 2 7 2 7
Baseline Mean 4.81 4.88 1.75 1.68 2.79 2.89 0.87 0.95
SD 0.95 0.90 0.44 0.49 0.86 0.73 0.35 0.36
Visit 2 Mean 4.64 4.41 1.70 1.62 2.72 2.59 0.87 0.91
SD 0.99 0.98 0.39 0.44 0.83 0.68 0.33 0.55
Change at V2 
from baseline
Mean -0.16 -0.47 -0.04 -0.05 -0.07 -0.30 0.00 -0.02
SD 0.43 0.52 0.19 0.19 0.36 0.43 0.28 0.40
Visit 3 Mean 4.40 4.1 1.63 1.59 2.56 2.41 1.01 0.94
SD 1.02 0.97 0.41 0.43 0.83 0.70 0.66 0.51
Change at V3 
from baseline
Mean -0.40 -0.70 -0.12 -0.08 -0.23 -0.48 0.14 0.01
SD 0.53 0.42 0.23 0.21 0.45 0.39 0.58 0.40
HDL = high density lipoprotein; LDL = low density lipoproteinNutrition Journal 2009, 8:9 http://www.nutritionj.com/content/8/1/9
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pharyngitis, food poisoning, rhinopharyngitis, neutrope-
nia, and three episodes of headache (for one subject) in
the control group, and one episode of headache and one
episode of soft stool in the study group. The adverse
events considered as "possibly" related to the use of the
test product were one episode each of flatulence in the
control group and the study group. One episode of nausea
in the test group was considered as "probably" related to
the test products intake. There were no serious adverse
events reported during the study. All subjects completed
the 21-day study.
Discussion
Full agreement on the distinction between different types
of dietary fiber has not been reached. However, focusing
on the IOM's most recent report on the subject, total die-
tary fiber is defined as the sum of dietary fiber and func-
tional fiber, therefore allowing for the diversity of edible,
non-digestible carbohydrates and for flexibility to incor-
porate new fiber sources developed in the future [1].
There are large variations in the physical and chemical
characteristics of dietary fiber that influence physiological
responses in humans differently. Gums, which are
hydrophilic polymers with significant water binding capa-
bility display unique physicochemical properties that
allow them to form viscous solutions or gels when mixed
with liquids. Because of these exceptional characteristics,
when gums are mixed with food and human digesta in the
stomach, a firm soluble polysaccharide/food matrix is
formed leading to a delay in gastric emptying which was
found to have several effects with possible physiological
ramifications including (1) increased sensation of fullness
[4], (2) possible reduction of postprandial blood glucose
concentrations, potentially increasing glucose sensitivity
[3], (3) delayed absorption of several nutrients in the
small intestine [4,12], possibly resulting in decreased
absorption of energy [13], (4) interference with the
absorption of dietary fat and cholesterol with an overall
result of decreased concentrations of blood cholesterol
[6,14], and (5) slower transit time through the small
intestine [3]. One study assessed the viscosity of different
Table 3: Uric acid and gamma-glutamyl transpeptidase (GGTP) levels at baseline, V2 and V3 (N = 54)
Uric acid (μmol/l) GGTP (IU/l)
Control PGX Control PGX
N2 7 2 7 2 7 2 7
Baseline Mean 276.4 274.2 27 27
SD 58.9 80.1 16.4 19.3
Visit 2 (V2) Mean 256.7 273.3 16.1 17.7
SD 57.2 72.1 6.1 8.2
Change at V2 from baseline Mean -19.7 -0.9 - 0.3 - 1.7
SD 29.5 35.9 1.6 2.9
Visit 3 (V3) Mean 250.4 256.4 14.9 16.8
SD 53.0 68.3 6.1 9.2
Change at V3 from baseline Mean -26.0 -17.8 - 1.5 -2.6
SD 34.6 34.4 3.0 4.0
GGTP = gamma-glutamyl transpeptidase; IU/l- International units per liter
Table 4: Levels of 1,25 dihydroxyvitamin D and Vitamin C at baseline, V2 and V3 (N = 54)
1,25 OH Vitamin D (ng/l) Vitamin C (μmol/l)
Control PGX Control PGX
N2 7 2 7 2 7 2 7
Baseline Mean 52.67 50.52 22.53 24.13
SD 17.55 15.70 18.98 15.60
Visit 2 Mean 56.22 71.44 31.64 36.11
SD 18.88 28.98 19.23 16.93
Change at V2 from baseline Mean 3.56 20.93 9.10 11.98
SD 20.84 24.30 15.47 14.46
Visit 3 Mean 49.67 48.26 29.16 37.22
SD 21.67 14.11 15.19 13.72
Change at V3 from baseline Mean -3.00 -2.26 6.62 13.09
SD 15.47 20.39 17.55 12.86Nutrition Journal 2009, 8:9 http://www.nutritionj.com/content/8/1/9
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soluble and insoluble dietary fibers, and found that guar
and xanthan gums had the highest viscosities, regardless
of concentration and exhibited this characteristic through-
out gastric and small intestinal simulation, indicating
potential to elicit blood glucose and lipid attenuation
[15].
In addition to the definition for dietary fiber, the amount
required to impact health is also debatable. For example,
IOM established an Adequate Intake (AI) recommenda-
tion for total fiber intake, based on age and sex. For adults
50 years of age and younger, the AI recommendation for
total fiber intake is 38 g per day for men and 25 g per day
for women, while for adults over 50 years of age, the rec-
ommendation is 30 g per day for men and 21 g per day for
women. IOM did not set a Tolerable Upper Intake Level
(UL) for dietary fiber or functional fiber [1]. On the other
hand, FDA bases its recommendation for fiber on caloric
intake. The percent daily value (DV) recommended by the
FDA for dietary fiber for individuals consuming 2,000
kcal/day is 25 g, and 30 g for those consuming 2,500 kcal/
day (21 CFR §101.9(d)(9)). However, it is evident that the
intake of dietary fiber in the United States is significantly
lower that the recommended amounts, as reflected by
intake data from the Continuing Survey of Food Intakes
by Individuals (CSFII) (1994–1996, 1998) [16] – median
intakes of dietary fiber ranged from 16.5 to 17.9 g/d for
men and 12.1 to 13.8 g/d for women. Based on the AI set
for the various age and gender groups, 10 percent or less of
a particular group consumed greater than the recom-
mended AI [1].
PolyGlycopleX (PGX) is a proprietary product composed
of three, highly-purified, water-soluble polysaccharides
(konjac powder, sodium alginate, and xanthan gum)
manufactured with the use of novel technology. The three
gums act synergistically to form strong bonds that lead to
a level of viscosity that is 3 to 5 times higher than any
known individual polysaccharide. The final product is a
soluble highly viscous functional fiber that can be used to
provide consumers with a supplementary source of fiber
in the diet.
Because of its potential use in food and dietary supple-
ments, the present investigation was carried out to evalu-
ate the tolerance to ingestion of 10 g PGX per day, for 21
days, in healthy male and female volunteers. The main
objective of the study was to evaluate the overall GI toler-
ance, while secondary objectives were to evaluate GI signs
and symptoms and assess any effects on blood hematol-
ogy, biochemistry, urine and stool analysis. The protocol
was developed to mimic as closely as possible a normal
lifestyle and dietary intakes of healthy subjects, who did
not go through a "wash out period" prior to being intro-
duced to the test and control products. Instead, a one-
week ramp-up period was used to acclimate the subjects
to the new products (2.5 g BID). The maximum dose of 10
g PGX per day was selected based on literature values that
indicate that the general population probably falls into
three categories, with regards to tolerance to dietary fiber:
(1) non-sensitive individuals, able to consume ≥ 30 g/day
of fiber without experiencing undesirable gastrointestinal
effects, (2) sensitive individuals, able to consume 10 g/day
of fiber without undesirable gastrointestinal effects, but
showing effects at ≥ 20 g/day, and (3) very sensitive indi-
viduals, who can experience undesirable gastrointestinal
effects at levels of ≤ 10 g/day [17]. Also taken into consid-
eration were the facts that dietary fibers are better toler-
ated if intake is in the form of solid versus liquid, and in
divided versus single doses [18].
All the subjects enrolled in the trial completed the study.
There were no serious adverse events and the adverse
events reported were of a mild to moderate nature, and
specific to GI discomfort (e.g., flatulence, bloating, intesti-
nal rumbling, or abdominal pain). FDA defines a serious
adverse event as "an adverse event that results in death, a
life-threatening experience, inpatient hospitalization, a
persistent or significant disability or incapacity, or a con-
genital anomaly or birth defect; or requires, based on rea-
sonable medical judgment, a medical or surgical
intervention to prevent an outcome described above"
(Section 761(a)(2) of the FD&C Act (21 U.S.C. 379aa-
1(a)(2)). An adverse event is defined as "any health-related
event associated with the use of a dietary supplement that
is adverse" (Section 761(a)(1) of the FD&C Act (21 U.S.C.
379aa-1(a)(1)). The intensity of abdominal pain and nau-
sea were somewhat higher, but not statistically significant
in the test (PGX) than in the control group, as reported in
subjects' diaries. However, this was not reflected by VAS
assessment. The GI complaints experienced by the sub-
jects in this study including flatulence, bloating, abdomi-
nal distension and rumbling are well described in the
literature [1], and are accepted occurrences with dietary
intake of fruits and vegetables, and fiber in general [8].
There are limited studies to suggest that chronic high
intakes of dietary fiber can cause gastrointestinal distress.
The ingestion of wheat bran at levels up to 40 g/day did
not result in significant increases in GI distress compared
to placebo [19]. However, flatulence did increase with
increased intake of dietary fiber in general [20], and with
gums that led to moderate to severe degrees of flatulence
in a trial in which 4 to 12 g/day of a hydrolyzed guar gum
were provided to 16 elderly patients [21].
In the present study, none of the subjects experienced
diarrhea (diarrhea is defined as an abnormally frequent
discharge of semisolid or fluid fecal matter from the
bowel, while laxation is a bowel movement [11]); how-Nutrition Journal 2009, 8:9 http://www.nutritionj.com/content/8/1/9
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ever, the consistency of stools was softer in the test than
control group at V2, although the difference was not sta-
tistically significant. The softer stools correlate with the
results from the stool analysis that showed that the dry
matter (%) was statistically higher in the control than in
the test (PGX) group at V2. The stool softness difference
was no longer present at the V3 visit, and corresponds to
those documented by the IOM report indicating that vis-
cous fiber generally has little effect on fecal bulk or laxa-
tion [1].
Statistical analysis showed no differences between test
and control group with regard to urinalysis or hematolog-
ical values. Although the authors believe that PGX is a fer-
mentable fiber, the stool analysis for SCFA showed no
differences between test and control groups. SCFA are
highly labile and it is possible that the amount of time
that lapsed between sample collection to the time of anal-
ysis was too long, possibly affecting the over all results.
The biochemical parameters were evaluated at baseline,
V2 and V3 and showed no differences between test and
control group, except for statistically significant decreases
in total cholesterol, and LDL cholesterol at V2 and V3, and
for GGTP and uric acid at V2.
PGX's effects on decreasing total and LDL cholesterol lev-
els in the study concur with similar reports in the litera-
ture describing the effects viscous dietary fiber has on
lowering serum cholesterol levels [1]. Noteworthy is the
fact that not all dietary fibers decrease serum cholesterol
concentration, or at least not to the same extent, with vis-
cous fibers being most successful. Behall [22] examined
the effects a low- and high-fiber diet had on plasma cho-
lesterol concentrations. The high-fiber diet of an average
of 19.5 g/day was further divided into non-viscous fiber
(cellulose), and viscous fiber (carboxymethylcellulose
gum, karaya gum, or locust bean gum). Results showed
that diets containing viscous dietary fiber led to signifi-
cantly lower plasma cholesterol concentrations. Jenkins et
al. [23] reported the hypocholesterolemic effect of guar
gum in the mid 1970s, followed in the 1980s by other
studies that showed a significant reduction in serum cho-
lesterol concentrations of between 11 and 16 percent [23-
25]. Anderson et al [26] demonstrated that when 20
hypercholesterolemic men were randomly assigned to
either a wheat bran or oat bran diet, a significant decrease
in serum total cholesterol concentration of 12.8 percent
was noted only after 21 days; however, this effect was not
seen in the wheat bran group.
Two meta-analyses evaluating the effects of viscous fiber
arrived at the same conclusions. One meta-analysis of 20
trials that used high doses of the viscous fiber oat bran,
showed that the reductions in serum cholesterol concen-
trations ranged from 0.1 to 2.5 percent/g of intake [27],
while another, evaluating the effects of oat bran, pectin,
psyllium and guar gum on blood lipid concentrations
showed that 2 to 10 g/day of viscous fiber were associated
with small but significant decreases in total and LDL cho-
lesterol concentrations [28].
IOM also concluded that viscous dietary and functional fib-
ers reduce both total and LDL cholesterol concentrations,
and possibly serum triglycerides in a dose-dependent
manner, although the report acknowledges that only few
studies report dose-response data. Further, the report indi-
cates that these relatively small-scale intervention trials
using viscous functional fibers have reported substantial
cholesterol-lowering effects and therefore, probably have
protective effects against coronary heart disease (CHD)
[1].
The GGTP levels were statistically lower in the PGX group
compared to controls. While the exact mechanism that led
to this decrease is not fully understood, especially because
the other liver enzymes were not altered, it is the belief of
the investigators that this decrease is beneficial, as eleva-
tion in GGTP is used to assess possible damage to the liver
or the biliary system.
Elevated levels of uric acid are associated with gout and
recently have been considered important markers for
hypertension, cardiovascular disease and metabolic syn-
drome [29]. While most studies have focused on hyperu-
ricemic states caused by either over production or under
excretion of uric cid, as well as by excessive intake of ribo-
nucleic acid (RNA), few studies have been devoted to
hypourecemia, or the effects of maintaining low uric acid
levels in otherwise healthy individuals [30]. Specifically,
the effect of dietary fiber on serum uric acid levels has
been only minimally investigated. Koguchi et al. [31] have
shown that feeding rats a diet high in viscous fiber (e.g.,
xanthan gum) they were able to alter metabolic processes
that contribute to hyperurecemia by lowering serum uric
acid levels, reducing RNA digestion and increasing RNA
excretion in the feces [31], a mechanism that probably
also explains the statistically lower levels of serum uric
acid identified in this clinical study at the V2 visit.
Lastly, the serum levels of several fat- and water soluble
vitamins were assessed during the study. Vitamin D was
measured because PGX demonstrates specific physical
properties including high viscosity and solubility and,
there was concern for possible sequestration of fat soluble
vitamins and therefore vitamin malabsorption. Conse-
quently, vitamin A, D, E and K levels were monitored dur-
ing the study. Vitamin C and B levels were followed as an
assessment of the potential of PGX to result in generalized
malabsorption. Results showed that there were no differ-Nutrition Journal 2009, 8:9 http://www.nutritionj.com/content/8/1/9
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ences observed in the levels of vitamin A, B1, B6, B12, E,
and K between test and control group, except for statisti-
cally higher levels of plasma vitamin D (1,25-dihydroxy-
vitamin D) and C. Vitamin D is a fat soluble vitamin
found only in few foods and produced endogenously with
exposure to sunlight. The vitamin D ingested or produced
is inactive (25-hydroxyvitamin D [25(OH)D] (calcidiol))
and undergoes activation through a two-step hydroxyla-
tion process in the liver and kidneys to form 1,25-dihy-
droxyvitamin D [1,25(OH)2D] (calcitriol). According to
the National Institutes of Health/Office of Dietary Supple-
ments (NIH/ODS), circulating 1,25(OH)2D is generally
not a good indicator of vitamin D status, because it has a
short half-life of 15 hours and serum concentrations are
closely regulated by calcium, phosphate and parathyroid
hormone. Further, levels of 1,25(OH)2D do not decrease
until vitamin D deficiency is severe [32]. Adequate levels
of vitamin D are essential for bone and overall health.
However, it has been determined that 41 percent of Amer-
ican men and 53 percent of American women have levels
of vitamin D below what is considered optimum. A recent
study found that a low serum level of 25-hydroxyvitamin
D could be independently associated with a significantly
increased risk of all-cause mortality. According to the
authors, if these findings are confirmed in future clinical
studies, vitamin D supplementation should be studied as
a way to reduce mortality risk [33].
Interestingly, optimal serum concentrations of 25(OH)D
have not been established [34,35] and are likely to vary at
each stage of life. NIH considers a concentration of <50
nmol/L 25(OH)D generally inadequate. In 2007, a con-
troversial editorial was published contending that supple-
mental intakes of 400 International Units (IU)/day of
vitamin D increase 25(OH)D concentrations by only 2.8–
4.8 ng/mL (7–12 nmol/L) and that daily intakes of
approximately 1,700 IU are needed to raise these concen-
trations from 20 to 32 ng/mL (50 to 80 nmol/L) [36]. The
exact mechanism leading to higher levels of serum
1,25(OH)2D in our study is not completely understood,
or interpreted as a good indicator of vitamin D status.
However, based on evidence that subnormal levels of vita-
min D can impact bone and overall health, and that
according to some investigators, current recommenda-
tions for supplementation of the US population is approx-
imately 4-fold lower than it should be, it is likely that
consumers could benefit from increased levels of serum
vitamin D to provided the necessary health benefits.
The exact mechanism causing increase in the serum vita-
min C levels in the test group is not completely under-
stood; however, as a water soluble vitamin, the somewhat
higher levels are not anticipated to have any detrimental
effects in otherwise healthy subjects.
The effects of the intervention on dietary intakes were not
measured in this clinical trial, because the focus of the
study was on assessing GI tolerance. However, this inten-
tional omission could be interpreted as a limitation of the
study, which the authors plan in addressing in future clin-
ical trials.
Conclusion
PGX, a novel, soluble and highly viscous functional fiber
showed in clinical testing to be well tolerated by healthy
male and female subjects when used to supplement the
diet for up to 10 g per day. Because the intake of dietary
fiber is significantly lower that the recommended amount
for the US population, the addition of PGX to a regular
diet will benefit consumers by increasing the overall fiber
intake; and because of its unique composition generating
a 3 to 5 times higher viscosity that any single polysaccha-
ride, this functional fiber can also provide consumers with
added physiological benefits including, but not limited to
maintenance of healthy total and LDL cholesterol and uric
acid levels.
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